(NASDAQ: TGTX) Tg Therapeutics's forecast annual revenue growth rate of 29.48% is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 33.67%, and while it is forecast to beat the US market's average forecast revenue growth rate of 14.07%.
Tg Therapeutics's revenue in 2026 is $700,349,000.On average, 10 Wall Street analysts forecast TGTX's revenue for 2026 to be $141,470,659,621, with the lowest TGTX revenue forecast at $133,188,837,943, and the highest TGTX revenue forecast at $151,093,493,460. On average, 9 Wall Street analysts forecast TGTX's revenue for 2027 to be $188,445,886,980, with the lowest TGTX revenue forecast at $152,708,525,229, and the highest TGTX revenue forecast at $257,180,414,400.
In 2028, TGTX is forecast to generate $231,921,623,700 in revenue, with the lowest revenue forecast at $203,754,244,980 and the highest revenue forecast at $251,363,238,360.